2024
Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
Moura F, Bellavia A, Berg D, Melloni G, Feinberg M, Leiter L, Bohula E, Morrow D, Scirica B, Wiviott S, Sabatine M. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obesity And Metabolism 2024, 26: 4441-4449. PMID: 39056220, PMCID: PMC11410501, DOI: 10.1111/dom.15798.Peer-Reviewed Original ResearchNew-onset diabetesRisk of new-onset diabetesClinical risk modelWeight loss therapyRisk groupsWeight loss pharmacotherapyMultivariate Cox regressionStable cardiovascular patientsTherapeutic decision makingAbsolute risk reductionHigh-risk groupType 2 diabetesIndependent predictorsValidation cohortFollow-upPersonalized patient careCox regressionHazard ratioPrimary outcomeRisk modelHigh riskInterquartile rangePatientsDiabetesCardiovascular patients
2022
Abstract 12593: Type 2 Diabetes Mellitus Polygenic Score Predicts New Onset Diabetes in Patients With Established Atherosclerotic Cardiovascular Disease: A FOURIER Sub-Study
Moura F, Kamanu F, Wiviott S, Giugliano R, Florez J, Roselli C, Keech A, Lubitz S, Ellinor P, Ruff C, Marston N, Sabatine M. Abstract 12593: Type 2 Diabetes Mellitus Polygenic Score Predicts New Onset Diabetes in Patients With Established Atherosclerotic Cardiovascular Disease: A FOURIER Sub-Study. Circulation 2022, 146: a12593-a12593. DOI: 10.1161/circ.146.suppl_1.12593.Peer-Reviewed Original ResearchNew-onset T2DPolygenic scoresGenetic riskClinical risk factorsAtherosclerotic cardiovascular diseaseGenome-wide significant single nucleotide polymorphismsGenetic risk categoriesAmerican Diabetes Association definitionRisk factorsCardiovascular diseaseSignificant single nucleotide polymorphismsPredicting new-onset diabetesBMI levelsNew-onset diabetes casesAssociation definitionType 2 diabetesNormal weightBaseline ageDiabetes casesNew-onset diabetesPre-diabetesSub-studySingle nucleotide polymorphismsBMIT2D